Knowing the rules is what lets you avoid the walls. This page walks you through Algeria's pharma sanctions level by level — starting with the Penal Code basics most training never covers, then every category of sanction identified in the regulations in force, in plain language, with the exact legal wording alongside.
Nothing is skipped — every sanction identified in the regulations in force lives in one of these levels. Jump to the one you need, or go through them in order, start to finish.
4 definitions nobody explains, in plain language
Establishments, GMP inspections, import/distribution
Placing products & devices on the market
Narcotics, falsified medicines, radionuclides, blood
Rules on promoting pharmaceutical products
Post-market safety obligations
Sponsor, investigator & consent obligations
General Titre VIII provisions beyond pharma establishments
The cross-cutting rules: additional penalties & the company
Three things nobody hands a directeur technique — or anyone else in a regulated pharma role — on day one, and that make every sanction below easier to read: the vocabulary itself, who actually regulates what, and four ideas from the general Penal Code. None of this is about fear — it's what lets you understand who a sanction targets and how it works, calmly.
Four words that come up constantly and are rarely defined out loud. They aren't pharma-specific — they're the vocabulary of Algerian law in general, and once they click, every sanction on this page reads more clearly.
A negative legal consequence attached to breaking a rule. It can be penal (decided by a court), administrative (decided by an authority like ANPP or the MIPP), or disciplinary (decided by a professional order).
The measurable content of a sanction — the actual prison term, the fine amount, the specific corrective measure. If « sanction » is the category, « pénalité » is the figure attached to it.
The broad family: being answerable, under any branch of law — civil, administrative, penal or disciplinary — for an act or omission. It's the umbrella term; penal responsibility is only one branch of it.
The specific branch that can lead to prison or a criminal fine, decided by a court once the elements of an offence are established. Art. 51 bis just below is what extends this to companies too, alongside the individual.
Three different bodies, three different roles. Knowing which one you're dealing with tells you what kind of answer to expect — and how fast.
Ministère de l'Industrie Pharmaceutique — the tutelle. Sets national pharmaceutical policy, drafts the decrees (Décret 20-325, 21-82…) — and, per Décret 21-82 itself, is also the one who actually signs the establishment agrément: its delivery, suspension and withdrawal (art. 16, 21, 26). ANPP inspects and instructs the file; the Minister decides it.
SIGNS THE AGRÉMENTAgence Nationale des Produits Pharmaceutiques — the operational regulator you deal with directly for registration/homologation, inspections, pharmacovigilance and lot recalls. It's ANPP's Director General who signs registration/homologation decisions (Décret 20-325/20-324) — but establishment agrément itself (Décret 21-82) is the Minister's signature, above, based on ANPP's inspection.
SIGNS REGISTRATION/HOMOLOGATIONWhere the prison terms and penal fines of Titre VIII (art. 400–441) are decided. Which court hears the case depends on the quantum: Art. 5's tripartite split sends contraventions to the tribunal de police, délits to the tribunal correctionnel, and crimes to the cour criminelle.
PENAL JURISDICTIONTwo different families of text, with two different origins. Knowing which is which tells you exactly where to check the wording yourself.
| Family | Root text | What it covers on this page |
|---|---|---|
| Penal sanctions (prison, criminal fines) | Loi n°18-11 of 2 July 2018 (the health law) — its own Titre VIII, « Dispositions pénales » (art. 400 to 441) | Every sanction card on Levels 2–8 and the cross-cutting rules below — a self-contained title inside the health law, not the general Penal Code. A couple of these articles (413, 416) do refer onward to the Penal Code for their exact quantum, but the offence itself is defined in Loi 18-11. |
| General principles behind every article above | Code pénal — Ordonnance n°66-156 of 8 June 1966, as amended | Not a pharma-specific source — it's where Level 1's four ideas come from (legality, individual/company liability, main/additional penalty, recidivism), which every Titre VIII article relies on. |
| Administrative sanctions (agrément, enregistrement/homologation, cahiers des charges) | A chain of décrets exécutifs implementing Loi 18-11 — Décret 21-82 (establishments), Décret 20-325 (registration), Décret 20-324 (DM homologation), Décret 22-247 (GMP) — each further detailed by ministerial arrêtés | Level 2's agrément table, Level 3's registration/homologation tables, and the cahiers des charges rows — none of these are published in the JORADP as sanctions in their own right; they're decided directly by the Minister or ANPP's Director General and notified to the establishment concerned. |
This is the pattern repeated through every level below: a sanction card with a bare article number belongs to Loi 18-11's Titre VIII (art. 400–441); a table naming a décret belongs to that décret's own text.
Source: Loi n°18-11 of 2 July 2018 (JORA n°46 of 29 July 2018); Code pénal, Ordonnance n°66-156 of 8 June 1966, as amended; Décrets exécutifs 20-324, 20-325, 21-82 and 22-247.
Two tracks run independently, and often at the same time: the administrative track (the Minister for agrément, ANPP for registration/homologation, table above) never goes near a court. A criminal referral is a completely separate track, governed by the Code de procédure pénale (last reformed by Loi n°25-14 of 3 August 2025). Here's what it actually looks like, step by step.
| Step | What happens | Who's involved |
|---|---|---|
| 1. The offence is recorded | An ANPP inspector or an officier de police judiciaire establishes a procès-verbal describing exactly what was found — this document is what everything downstream is built on. | ANPP inspector, or police judiciaire |
| 2. It reaches the Procureur de la République | The procès-verbal is transmitted to the Procureur, who decides what happens next: pursue it, dismiss it (classement sans suite), or — since the 2025 reform — offer an alternative such as criminal mediation or, for a company, a suspended prosecution if it restores funds and reforms internally. | Procureur de la République |
| 3. Instruction, if the case needs it | For more serious or complex matters, a juge d'instruction investigates further — interrogations, expert reports, searches. Simpler délits can go straight to trial by citation directe, skipping this step. | Juge d'instruction (when opened) |
| 4. Trial, before the right court | Which court depends on the offence's severity — Art. 5's tripartite split, already covered above: tribunal de police for contraventions, tribunal correctionnel for délits, cour criminelle for crimes. | The competent tribunal |
| 5. Sentence, and possibly appeal | The court hands down the peine principale (prison/fine) and any peine complémentaire it adds on top (Art. 9, Level 1). Like most first-instance judgments, this can generally be appealed. | The tribunal, then the cour d'appel |
Because Art. 51 bis (Level 1, above) makes the company itself criminally liable alongside the individuals who acted, both can go through this exact same sequence — often in the same case. One more nuance from the 2025 reform: its new protection against prosecution without the company's own prior complaint is written for managers of entreprises publiques économiques (state-owned companies) — it isn't a blanket shield for every private pharma establishment, so check your establishment's status before assuming it applies.
Source: Code de procédure pénale, dorénavant régi par la loi n°25-14 du 3 août 2025 (JORADP n°54 du 13 août 2025), general procedural roles cross-checked against the consolidated text on WIPO Lex.
These four come from the general Algerian Penal Code (Ordonnance n°66-156 of 8 June 1966, as amended) — not from Loi 18-11. They apply to every profession, not just pharma.
No one can be punished for something the law didn't define in advance as an offence. That's precisely why the sanctions on this page are written out in such precise detail: the exact wording is your best protection, because it draws the line of what is, and isn't, punishable.
This isn't a pharma-specific idea: since 2004, Algerian law recognizes that a company can be criminally liable in its own right, alongside — not instead of — the individual who acted. Understanding this early helps you see clearly, for any sanction, which of the two tracks (or both) applies.
A main penalty (Art. 5) is the prison term or fine attached directly to an offence. An additional penalty (Art. 9) is a further measure — confiscation, a ban on practicing, closing a site — that a court can add on top. When a sanctions table below lists both, this is the distinction it's drawing.
A repeat offence, committed within a defined period after a final conviction for a similar one, triggers an aggravated penalty. This is exactly why, further down, you'll see « doubled on repeat offence » next to the advertising sanction — it's this general rule being applied.
Source: Code pénal algérien — Ordonnance n°66-156 du 8 juin 1966, telle que modifiée (notamment par la loi n°14-01 du 4 février 2014), texte consolidé WIPO Lex.
Most of the sanctions in this category exist to protect one thing: that an establishment only does what its agrément allows, the way it was inspected to do it. Here is exactly where the lines are.
This is Titre VIII's most-applied article — and Level 1's Art. 51 bis is why both the company and the individuals involved can face it.
| Risk level | Criteria | Consequence |
|---|---|---|
| Risk 1 — Critical | Direct impact on quality, safety or efficacy; data integrity failure; a repeated finding after insufficient CAPA | Automatic Non-Conforming rating; immediate corrective action; possible agrément suspension, registration withdrawal, penal referral |
| Risk 2 — Major | ≥3 Risk-2 findings, or a major systemic issue | Non Conforming if ≥3 findings or systemic; CAPA under a strict deadline; follow-up inspection possible |
| Risk 3 — Other (minor) | Minor, non-systemic gaps, generally ≤3 isolated findings | Conforming rating; CAPA recommended, no immediate corrective measure |
Good to know: a finding similar to a previous one, where CAPA didn’t prevent it recurring, can be reclassified upward — that's worth flagging early to your quality team, not discovering at the next inspection.
| Situation | What follows |
|---|---|
| Finding at inspection, formal notice not acted on (Art. 26, Décret 21-82) | Temporary closure ≤1 year (reopening only after reservations are lifted), or definitive agrément withdrawal |
| GMP non-compliance found at inspection (Déc. 22-247, art. 28) | Same ladder: temporary closure ≤1 year or definitive withdrawal |
| Establishment not operational within 2 years of agrément (Art. 23, Décret 21-82) | Agrément becomes void — one 1-year extension possible on justification |
| Import technical-conditions cahier des charges breached (Art. 31, cahier des charges importation) | Termination of the cahier des charges |
| Wholesale-distribution cahier des charges breached (Art. 23–25, cahier des charges distribution en gros) | Termination of the cahier des charges; applicable regulatory sanctions |
Sanction: administrative (decided by the Minister in charge of the pharmaceutical industry, per Décret 21-82 art. 16 & 21 — not ANPP, and not a court. ANPP's inspectors are usually the ones on site and the ones who send the mise en demeure, but the closure/withdrawal decision itself is the Minister's signature) — Pénalité: temporary closure, void or terminated agrément/cahier des charges, as listed above. Persons concerned: the establishment as a whole, its legal representative, and its directeur technique, who is usually the first point of contact for ANPP's inspectors.
Every step of this — the formal notice, the withdrawal decision itself — travels through a secure remote electronic channel, not paper. That level of procedural detail is confirmed for wholesale-distribution and importation establishments (arrêtés of 30 September and 1 October 2025 respectively — both signed by Ouacim KOUIDRI, both published in the JORADP over five months later, in March 2026). It doesn’t carry over evenly: the manufacturing arrêté (22 September 2025) has no withdrawal chapter at all, and the exploitation arrêté (1 October 2025) only covers voluntary cessation, not the non-compliance route. For those two establishment types, Décret 21-82 art. 26 above stays the only text spelling out what happens after an unanswered mise en demeure — the arrêtés add detail where they exist, they don’t take anything away where they're silent.
The registration decision is a living thing — it can be refused, suspended or withdrawn, and each of those has its own trigger and timeline. Knowing the clock lets you act before a temporary measure becomes definitive.
| Decision | Trigger | Timeline | What it means for you |
|---|---|---|---|
| Refusal (Art. 38) | Harmful product; insufficient efficacy; non-compliant file or manufacturing; unfavorable economic evaluation | Reasoned, notified by the ANPP DG | No market access — an appeal to the DG is possible |
| Temporary withdrawal (Art. 45) | Health-safety and/or quality risk detected on a registered product | 12 months to lift the reservations | This is the clock that matters most — see the note below |
| Definitive withdrawal (Art. 46–47) | Reservations not lifted in 12 months; safety/quality; or not marketed within 18 months of notification | DG ANPP decision after Commission opinion | Loss of the right to market in Algeria; recall costs on the operator |
| Voluntary withdrawal | Your own decision to discontinue | Reasoned request, decided after Commission opinion | The tidiest exit — plan it rather than let a deadline force it |
The one date to put in your calendar: a temporary withdrawal becomes definitive automatically at 12 months if reservations aren’t lifted — there is no separate reminder from ANPP.
| Decision | Trigger | Timeline |
|---|---|---|
| Refusal (Art. 31) | Altered characteristics/performance; incomplete file; safety risk | Reasoned, notified by the ANPP DG |
| Temporary withdrawal (Art. 38) | Safety and/or quality compromised | ≤12 months, same conversion rule as medicines |
| Definitive withdrawal (Art. 40–41) | Reservations not lifted in 12 months; safety/quality; not marketed within 18 months | DG ANPP decision after Commission d’homologation opinion |
Four categories of product carry the heaviest penalties in Titre VIII, precisely because the risk to patients is highest. These are worth knowing cold, not looking up under pressure.
The lightest sanction in Titre VIII in terms of quantum — no prison at all — but it's the one that puts Level 1's recidivism rule to work most visibly.
No penal quantum here — these are ANPP's own regulatory measures, decided independently of any court, and they move fast. Knowing the deadlines is what lets your team react inside them instead of finding out after the fact.
| Class | Definition | Deadline & obligations |
|---|---|---|
| Class I — Critical | Imminent danger to life or risk of irreversible disability; critical quality defect | Action within 48h. No suspension of the decision possible. Public notice if required. |
| Class II — Major | Temporary health problems; significant but not immediately life-threatening | Action within 72h. Review possible within 10 working days; final decision enforceable. |
| Class III — Minor | Minor defects, no serious health consequence | Less urgent; recall, correction and a documented report required. |
| Situation | What follows |
|---|---|
| Unfavorable benefit/risk report or unmanaged safety signal | Suspension or withdrawal of the registration/homologation decision |
| Defective or non-conforming lot detected post-marketing | Lot recall/withdrawal; destruction at the operator’s cost |
| Non-compliant or insufficient labelling, leaflet or SmPC | Mandatory update to conditions of use, labelling or instructions |
| Immediate public-health risk identified | Safety alert to healthcare professionals and the public |
| No pharmacovigilance system (missing PSMF, no QPPV/RLPV) | Corrective/corrective measures; possible withdrawal of the registration decision |
One habit worth building into your team's reflexes: any healthcare professional must report a suspected adverse effect to CNPM without delay, even without certainty — it's a duty, not an option.
Two articles here, and they target different people — the sponsor on one side, the investigator personally on the other. Worth clarifying who owns which obligation before a study starts, not during an inspection.
| Situation | What follows |
|---|---|
| Participant safety risk or major non-conformity detected | Immediate suspension or definitive stop of the study |
| Substantial amendment implemented before submission | Amendment invalidated; possible study stop by the ethics committee and/or MIP |
These four articles sit in the same Titre VIII, but they apply to any health professional or establishment, not just pharma. Good to have on your radar since a directeur technique is, first, a pharmacist — and since the rest of your team (prescribers, caregiving staff) can be reached by these too.
This is individual, personal criminal responsibility (Art. 413) — not the company’s, unlike most other cards on this page.
These two don't belong to one category — they sit on top of every offence in Titre VIII. Once you've read Level 1's note on individual vs. company liability, this is where it plays out in full.
On top of prison and fines, a court may add one or more further Penal Code measures — for any offence in Titre VIII. It's the same mechanism as Level 1's Art. 5 / Art. 9 distinction, just applied here.
The company answers in parallel to the individual — Level 1's Art. 51 bis in action — with a fine floor of 5× the personal maximum and, in the most serious cases, dissolution.
The takeaway: understanding Titre VIII isn't about memorizing every figure — it's about knowing these two rules apply everywhere, so you read every level above with the right lens.
Critical — prison range at the topHigh — loss of a right or authorizationModerate — fine or corrective measure only
A gap analysis against this map, a training session for your directeur technique and your whole RA team, or a RAPSKEY demo to track deadlines automatically — tell us what would help.
Contact us